Contact
searchSearch
HMP Global

Rheumatology Topic Center

Featured Article

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
News
Room for Improvement in Polymyalgia Rheumatica Referral, Management
01/26/2023
Jolynn Tumolo
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people...
01/26/2023
First Report Managed Care

Newsfeed

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
News
Mail-Based FIT Program Increases CRC Screening in a Value-Based Care System
04/13/2026
Rebecca Amrick
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health...
04/13/2026
First Report Managed Care
News
What Real-World Data Reveal About R/R DLBCL Care
04/13/2026
Rebecca Amrick
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments...
04/13/2026
First Report Managed Care
News
Delays in Early-Stage NSCLC Surgery Linked to Systemic and Equity Gaps in Patients
04/13/2026
Rebecca Amrick
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among...
04/13/2026
First Report Managed Care
News
Epcoritamab Plus R2 Maintains Quality of Life in R/R Follicular
04/10/2026
Hannah Musick
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and...
04/10/2026
First Report Managed Care
Behind the Bill
CMS Proposes FY 2027 Skilled Nursing Facility Payment and Quality Updates
04/10/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare &...
04/10/2026
First Report Managed Care
News
Bispecific Antibodies in Non-Hodgkin Lymphoma Show Manageable Safety Profile in Meta-Analysis
04/10/2026
Rebecca Amrick
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in...
04/10/2026
First Report Managed Care
News
Outpatient Cilta-cel Shows Promise in Multiple Myeloma, With Early Signs of Lower Costs and Comparable Outcomes
04/09/2026
Rebecca Amrick
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review...
04/09/2026
First Report Managed Care
News
Epcoritamab Expands Treatment Options in Relapsed or Refractory Follicular Lymphoma
04/08/2026
Hannah Musick
Epcoritamab is emerging as a promising, subcutaneous bispecific antibody option for relapsed or refractory follicular lymphoma, offering high response rates and a manageable safety profile in heavily pretreated patients.
Epcoritamab is emerging as a promising, subcutaneous bispecific antibody option for relapsed or refractory follicular lymphoma, offering high response rates and a manageable safety profile in heavily pretreated patients.
Epcoritamab is emerging as a...
04/08/2026
First Report Managed Care
News
Amivantamab Plus Lazertinib Expands Options for Atypical EGFR NSCLC
04/07/2026
Hannah Musick
Amivantamab plus lazertinib shows promising and durable activity in patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations, offering a potential new treatment option for...
Amivantamab plus lazertinib shows promising and durable activity in patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations, offering a potential new treatment option for...
Amivantamab plus lazertinib...
04/07/2026
First Report Managed Care
News
Machine Learning Model Identifies Early Adalimumab Discontinuation Risk in Rheumatoid Arthritis
04/07/2026
Hannah Musick
A machine learning model using specialty pharmacy data accurately identified patients with rheumatoid arthritis at high risk of early adalimumab discontinuation, enabling targeted interventions to improve outcomes and reduce medication waste.
A machine learning model using specialty pharmacy data accurately identified patients with rheumatoid arthritis at high risk of early adalimumab discontinuation, enabling targeted interventions to improve outcomes and reduce medication waste.
A machine learning model using...
04/07/2026
First Report Managed Care

Insights

Interview
Lower Costs, Improved Outcomes for Patients Achieving Early RA Remission
07/23/2019
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD,...
07/23/2019
First Report Managed Care
Interview
Impact of Artificial Intelligence on Patient Outcomes, Cost of Care in RA
06/20/2019
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar...
06/20/2019
First Report Managed Care
Interview
High Out-of-Pocket Costs Increase Medication Nonadherence Among Patients With RA
06/06/2019
Julie Gould
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at...
06/06/2019
First Report Managed Care
Interview
Techniques Used to Lessen Opioid Use, Address Rheumatologic Pain
05/09/2019
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending...
05/09/2019
First Report Managed Care
Interview
Why Higher Levels of Physical Activity Are Important in Preventing Chronic Diseases
04/11/2019
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD,...
04/11/2019
First Report Managed Care
Interview
Assessing the Safety of a Treatment With A Label Warning for Patients With RA, COPD
04/08/2019
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of...
04/08/2019
First Report Managed Care
Interview
Exploring the Cost Benefits of Cloud-Enabled Testing for RA Diagnosis
03/14/2019
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research...
03/14/2019
First Report Managed Care
Interview
Improving Access to Care, Outcomes Through Telemedicine for Patients With RA
03/06/2019
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate...
03/06/2019
First Report Managed Care
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
First Report Managed Care
Al B. Benson, III, MD, FACP, FASCO
Videos
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Evidence Review
03/31/2026
Al B. Benson, III, MD, FACP, FASCO
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the...
03/31/2026
First Report Managed Care
Videos
Can Agentic AI Deliver? Rethinking Innovation, ROI, and Risk in Managed Care
03/30/2026
Andy De, CMO
A guest expert explains why generative AI has largely stalled in health care and argues that agentic AI—focused on automating workflows and driving action—offers a more practical path to measurable ROI, improved clinician productivity, and...
A guest expert explains why generative AI has largely stalled in health care and argues that agentic AI—focused on automating workflows and driving action—offers a more practical path to measurable ROI, improved clinician productivity, and...
A guest expert explains why...
03/30/2026
First Report Managed Care
MANAGED CARE Q&A
Why Emotional Readiness Matters in Specialty Drug Management
03/26/2026
Abby Reynolds, PharmD
In this interview, a guest expert explains why emotional readiness—not motivation or access alone—often determines whether patients can successfully initiate and persist on specialty therapies.
In this interview, a guest expert explains why emotional readiness—not motivation or access alone—often determines whether patients can successfully initiate and persist on specialty therapies.
In this interview, a guest...
03/26/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
MANAGED CARE Q&A
Beyond the Pharmacy Benefit: Managing Specialty Drug Costs in an Era of Rapid Growth
03/26/2026
Allison Oakes, PhD
A guest expert explains why specialty drugs dominating US spending is forcing payers to rethink benefit design, oncology strategy, and biosimilar adoption to control costs and improve value.
A guest expert explains why specialty drugs dominating US spending is forcing payers to rethink benefit design, oncology strategy, and biosimilar adoption to control costs and improve value.
A guest expert explains why...
03/26/2026
First Report Managed Care
ALH
Videos
Redefining gMG Management: Pt III
03/12/2026
Amanda L. Hernandez, MD, PhD
In the final installment of this interview, Amanda Hernandez, MD, PhD, explores how coverage design, route of administration, and formulary decisions influence access to emerging myasthenia gravis therapies, underscoring the need for...
In the final installment of this interview, Amanda Hernandez, MD, PhD, explores how coverage design, route of administration, and formulary decisions influence access to emerging myasthenia gravis therapies, underscoring the need for...
In the final installment of this...
03/12/2026
First Report Managed Care
ALH
Videos
Redefining gMG Management: Pt II
03/12/2026
Amanda L. Hernandez, MD, PhD
In the second part of this interview, Amanda Hernandez, MD, PhD, examines the role and limitations of Myasthenia Gravis Activities of Daily Living (MG-ADL)  and other outcome measures in myasthenia gravis, emphasizing the importance of...
In the second part of this interview, Amanda Hernandez, MD, PhD, examines the role and limitations of Myasthenia Gravis Activities of Daily Living (MG-ADL)  and other outcome measures in myasthenia gravis, emphasizing the importance of...
In the second part of this...
03/12/2026
First Report Managed Care
ALH
Videos
Redefining gMG Management: Pt I
03/12/2026
Amanda L. Hernandez, MD, PhD
In this interview, Amanda Hernandez, MD, PhD, discusses the evolving general myasthenia gravis (gMG) treatment landscape, highlighting the shift toward more targeted immunologic therapies, the challenges of step therapy, and the need for...
In this interview, Amanda Hernandez, MD, PhD, discusses the evolving general myasthenia gravis (gMG) treatment landscape, highlighting the shift toward more targeted immunologic therapies, the challenges of step therapy, and the need for...
In this interview, Amanda...
03/12/2026
First Report Managed Care
NSCLC, Oncology Coverage, Oncology Access
Videos
What PALOMA-3 Signals for Coverage, Access, and Care Delivery in NSCLC
02/02/2026
Narjust Florez, MD
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust...
02/02/2026
First Report Managed Care
First Report Managed Care

Current Issue

March 2026
Volume 23
Issue 1
Current Issue
Issue Archive

Recent Stories

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use